Yifan Xinfu Pharmaceutical Co Ltd (002019) — Strategic Asset Allocation Index
Yifan Xinfu Pharmaceutical Co Ltd (002019) has a Strategic Asset Allocation Index of 17.6% as of September 2023. Strategic assets (PP&E of CN¥1.63 Billion plus long-term investments of CN¥-) total CN¥1.63 Billion, measured against net assets of CN¥9.27 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Yifan Xinfu Pharmaceutical Co Ltd (002019) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Yifan Xinfu Pharmaceutical Co Ltd Strategic Asset Allocation Index (2001–2021)
This chart shows how Yifan Xinfu Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 21 annual periods from 2001 to 2021. As of September 2023, the index stands at 17.6%, representing strategic assets of CN¥1.63 Billion against net assets of CN¥9.27 Billion CNY. See Yifan Xinfu Pharmaceutical Co Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Yifan Xinfu Pharmaceutical Co Ltd (2001–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2021, covering 21 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 002019 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 18.7% | CN¥1.64 Billion | CN¥1.64 Billion | CN¥- | CN¥8.78 Billion | ▲ +1.6 pp |
| 2020 | 17.1% | CN¥1.49 Billion | CN¥1.49 Billion | CN¥- | CN¥8.72 Billion | ▲ +0.6 pp |
| 2019 | 16.5% | CN¥1.29 Billion | CN¥1.29 Billion | CN¥- | CN¥7.82 Billion | ▼ -0.2 pp |
| 2018 | 16.7% | CN¥1.15 Billion | CN¥1.10 Billion | CN¥43.74 Million | CN¥6.89 Billion | ▲ +1.5 pp |
| 2017 | 15.1% | CN¥1.03 Billion | CN¥909.58 Million | CN¥117.54 Million | CN¥6.78 Billion | ▼ -6.1 pp |
| 2016 | 21.3% | CN¥829.86 Million | CN¥820.02 Million | CN¥9.84 Million | CN¥3.90 Billion | ▼ -7.9 pp |
| 2015 | 29.2% | CN¥841.27 Million | CN¥838.51 Million | CN¥2.76 Million | CN¥2.88 Billion | ▲ +2.8 pp |
| 2014 | 26.4% | CN¥672.66 Million | CN¥672.66 Million | CN¥- | CN¥2.54 Billion | ▼ -118.5 pp |
| 2013 | 145.0% | CN¥558.00 Million | CN¥558.00 Million | CN¥- | CN¥384.95 Million | ▲ +32.2 pp |
| 2012 | 112.7% | CN¥542.09 Million | CN¥542.09 Million | CN¥- | CN¥480.81 Million | ▼ -15.8 pp |
| 2011 | 128.5% | CN¥603.35 Million | CN¥603.35 Million | CN¥- | CN¥469.52 Million | ▲ +35.9 pp |
| 2010 | 92.6% | CN¥651.50 Million | CN¥651.50 Million | CN¥- | CN¥703.64 Million | ▲ +30.7 pp |
| 2009 | 61.8% | CN¥564.71 Million | CN¥564.71 Million | CN¥- | CN¥913.15 Million | ▼ -21.0 pp |
| 2008 | 82.8% | CN¥472.69 Million | CN¥472.69 Million | CN¥- | CN¥570.87 Million | ▲ +10.6 pp |
| 2007 | 72.2% | CN¥395.90 Million | CN¥395.90 Million | CN¥- | CN¥548.55 Million | ▼ -15.9 pp |
| 2006 | 88.1% | CN¥285.92 Million | CN¥285.92 Million | CN¥- | CN¥324.46 Million | ▲ +7.2 pp |
| 2005 | 80.9% | CN¥259.78 Million | CN¥259.78 Million | CN¥- | CN¥320.93 Million | ▲ +27.5 pp |
| 2004 | 53.5% | CN¥165.76 Million | CN¥165.76 Million | CN¥- | CN¥309.98 Million | ▼ -71.7 pp |
| 2003 | 125.2% | CN¥118.08 Million | CN¥118.08 Million | CN¥- | CN¥94.31 Million | ▲ +44.6 pp |
| 2002 | 80.6% | CN¥64.01 Million | CN¥64.01 Million | CN¥- | CN¥79.43 Million | ▲ +1.9 pp |
| 2001 | 78.7% | CN¥41.15 Million | CN¥41.15 Million | CN¥- | CN¥52.31 Million | — |